SecBot SecBot
EFFECT ·Filed Nov 12, 2026

PROK

PROKIDNEY CORP.
BEARISH
Impact 5/10
Horizonweeks Processed4d 20h ago SEC9999999995-26-003506
IPO/offering going effective
Actionable Insight ▼ Bearish

Monitor for any takedown announcements under the shelf or ATM. The company's cash burn and development stage make future offerings likely, and any pricing update will signal near-term dilution magnitude.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.15
T+0 close · Nov 12, 2026 · via day close
Latest settled
−9.13%
T+1 · $1.05
Vs SPY
−8.77%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $1.15entry
  2. T+1 · 4d ago −9.13%α −8.77% · $1.05
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProKidney Corp.'s universal shelf registration (File No. 333-299700) became effective on November 10, 2026. This allows the company to sell up to $650 million in securities, including a $200 million ATM equity facility, creating potential dilution overhang for a pre-revenue biotech with no approved products.

Key Facts

  • Effectiveness date: November 10, 2026
  • Shelf registration file number: 333-299700
  • Up to $650 million in securities registered, including $200 million ATM facility
  • Company has no approved products and no revenue
  • Net tangible book value of $222.8 million as of June 30, 2026
  • ATM could increase share count by up to 63% at $1.52 per share

Financial Impact

Up to $650 million in potential dilution; ATM alone could add 63% to share count at current price

dilutionshare countcash balance

Risk Factors

  • Significant dilution risk from potential ATM or shelf takedowns
  • No approved products or revenue to offset dilution
  • Pre-revenue biotech with uncertain clinical and regulatory timeline

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-003506
Document: 9999999995-26-003506-index.html9999999995-26-003506
Document: 9999999995-26-003506.txt9999999995-26-003506

Track record

13 reports on PROK

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  3. Nov 12, 20265d ago EFFECT Bearish 5/10 Viewing Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  6. Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  7. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  9. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
  10. May 15, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026